New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer

  • Study

    Single-arm, multicenter, phase II trial
    HER2 positive, unresectable or metastatic gastric or gastro-oesophageal junction cancer, progressive disease on or after first-line therapy with a trastuzumab-containing regimen
    Trastuzumab-deruxtecan (n=79


  • Efficacy

    cORR: 42% [33 of 79 pts]
    CR: 5% [ 4 of 79 pts]
    mPFS: 5.6 mos [4.2-8.3]
    mOS: 12.1 mos [9.4-15.4]
    mDoR: 8.1 mos [5.9-NR]

  • Safety

    Grade3: Anemia (14%), nausea (8%), neutropenia (8%)


    • LANCET Oncol, VOL 24, ISSUE 7, P744-756, JUL 2023

    Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

    http://doi.org/10.1016/S1470-2045(23)00215-2

    Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag